Teca Partners LP Takes Position in Thermo Fisher Scientific Inc. $TMO

Teca Partners LP bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 3rd quarter, Holdings Channel reports. The fund bought 25,350 shares of the medical research company’s stock, valued at approximately $12,295,000. Thermo Fisher Scientific makes up 7.8% of Teca Partners LP’s portfolio, making the stock its 7th biggest position.

Other institutional investors also recently made changes to their positions in the company. Highline Wealth Partners LLC increased its stake in shares of Thermo Fisher Scientific by 126.9% during the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock worth $29,000 after purchasing an additional 33 shares during the period. Capital A Wealth Management LLC increased its position in Thermo Fisher Scientific by 825.0% during the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock worth $30,000 after buying an additional 66 shares during the period. Cloud Capital Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the third quarter worth $31,000. Howard Hughes Medical Institute acquired a new position in shares of Thermo Fisher Scientific in the second quarter valued at about $33,000. Finally, Elevation Wealth Partners LLC increased its position in Thermo Fisher Scientific by 35.1% during the third quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company’s stock worth $37,000 after acquiring an additional 20 shares during the period. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. UBS Group reissued a “neutral” rating and issued a $615.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, January 30th. KeyCorp upgraded shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target for the company in a research report on Sunday, December 7th. Evercore reiterated an “outperform” rating and issued a $650.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, January 5th. Barclays raised their price objective on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research note on Friday, January 30th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $633.68.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the sale, the executive vice president owned 20,752 shares in the company, valued at $11,230,982.40. The trade was a 1.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. The trade was a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

NYSE TMO traded down $3.43 on Friday, hitting $472.46. 422,081 shares of the company’s stock were exchanged, compared to its average volume of 2,437,779. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The stock has a market cap of $175.51 billion, a price-to-earnings ratio of 26.64, a P/E/G ratio of 2.86 and a beta of 0.96. The stock has a 50-day moving average of $560.39 and a 200-day moving average of $548.36.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, topping the consensus estimate of $6.45 by $0.12. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The firm had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same quarter in the previous year, the firm earned $6.10 earnings per share. The business’s quarterly revenue was up 7.2% on a year-over-year basis. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th will be given a $0.47 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Friday, March 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.70%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.